Penumbra (PEN) revenue breakdown
By product, Thrombectomy is the largest at 68% of fiscal 2025 revenue, growing 21% a year over 4 years.
By region, United States is the largest at 78% of fiscal 2025 revenue, growing 22% a year over 9 years.
Revenue by product
Fiscal years, as Penumbra reports them in its 10-K filings; fiscal 2025 total $1.4B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | — | — | — | — | — | $438M | $511M | $677M | $815M | $948M | 68% |
| Embolization and Other | — | — | — | — | — | $310M | $336M | $381M | $379M | $456M | 32% |
| Neuro | $186M | $232M | $294M | $332M | $293M | — | — | — | — | — | — |
| Vascular | $78M | $101M | $151M | $216M | $268M | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Penumbra reports them in its 10-K filings; fiscal 2025 total $1.4B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $176M | $219M | $291M | $355M | $400M | $528M | $592M | $757M | $902M | $1.1B | 78% |
| International | $57M | $81M | $154M | $192M | $160M | $220M | $255M | $301M | $293M | $312M | 22% |
| Japan | $30M | $34M | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PEN.
Open PEN in InvestinglyQuestions
Where does Penumbra make its money?
In fiscal 2025, by product: Thrombectomy $948M, Embolization and Other $456M.
From Penumbra's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.